Bodell William J
Laboratory of Molecular Therapeutics, Brain Tumor Research Center of the Department of Neurological Surgery, University of California-San Francisco, San Francisco, CA, 94143-0555, USA.
J Neurooncol. 2009 Feb;91(3):257-64. doi: 10.1007/s11060-008-9715-1. Epub 2008 Nov 2.
This study has investigated if individual DNA adducts formed in human glioma cells treated with (3)H-1-(2-chloroethyl)-1-nitrosourea ((3)H-CNU) could be used as molecular dosimeters of response after CENU treatment. The levels of individual DNA alkylation products were compared with the induction of cytotoxicity in six human glioma cell lines after treatment with (3)H-CNU. The levels of seven DNA adducts N7-(2-hydroxyethyl)guanine, (N7-HOEtG); N7-(2-chloroethyl)guanine, (N7-ClEtG); 1,2-[diguan-7-yl]-ethane, (N7-bis-G); N1-(2-hydroxyethyl)-2-deoxyguanosine, N1-HOEtdG; 1-[N1-2-deoxyguanosinyl], 2-[N3-2-deoxycytidyl]-ethane, dG-dC; O(6)-(2-hydroxyethyl)-2-deoxyguanosine, O(6)-HOEtdG and phosphotriesters (PTE), were quantified in each of the cell lines following treatment with (3)H-CNU. The levels of N7-HOEtG, N7-ClEtG; O(6)-HOEtdG and PTE were not significantly different in the glioma lines and their levels were not associated with the induction of cytotoxicity by CNU treatment. The levels of N7-bis-G, N1-HOEtdG and dG-dC crosslink were significantly lower in both SF-188 and SF-763 cell lines compared to their levels in U87MG, U251MG and SF-126. There was a significant correlation between CNU LD(10) values and with the levels of levels of N7-bis-G and N1-HOEtdG (R = -0.91, P = 0.01) and dG-dC crosslink (R = -0.94, P = 0.005) in the glioma cell lines. Pretreatment of SF-188 cells with varying concentrations of MNU prior to CNU treatment resulted in no change in the levels of N7-HOEtG, N7-ClEtG; O(6)-HOEtdG and PTE and a dose dependent increase in the levels of N7-bis-G, N1-HOEtdG and dG-dC crosslink. Taken together, these results suggest that the levels of the N7-bis-G, N1-HOEtdG and dG-dC crosslink could be used as molecular dosimeters of therapeutic response following treatment with BCNU or related CENU.
本研究调查了用(3)H-1-(2-氯乙基)-1-亚硝基脲((3)H-CNU)处理的人胶质瘤细胞中形成的单个DNA加合物是否可作为CENU治疗后反应的分子剂量计。将单个DNA烷基化产物的水平与用(3)H-CNU处理后的六种人胶质瘤细胞系中的细胞毒性诱导情况进行了比较。在用(3)H-CNU处理后,对七种DNA加合物N7-(2-羟乙基)鸟嘌呤(N7-HOEtG)、N7-(2-氯乙基)鸟嘌呤(N7-ClEtG)、1,2-[双鸟嘌呤-7-基]-乙烷(N7-双-G)、N1-(2-羟乙基)-2-脱氧鸟苷(N1-HOEtdG)、1-[N1-2-脱氧鸟苷基]、2-[N3-2-脱氧胞苷基]-乙烷(dG-dC)、O(6)-(2-羟乙基)-2-脱氧鸟苷(O(6)-HOEtdG)和磷酸三酯(PTE)在每个细胞系中的水平进行了定量。在胶质瘤细胞系中,N7-HOEtG、N7-ClEtG、O(6)-HOEtdG和PTE的水平无显著差异,且它们的水平与CNU处理诱导的细胞毒性无关。与U87MG、U251MG和SF-126中的水平相比,SF-188和SF-763细胞系中N7-双-G、N1-HOEtdG和dG-dC交联的水平显著较低。在胶质瘤细胞系中,CNU LD(10)值与N7-双-G和N1-HOEtdG的水平(R = -0.91,P = 0.01)以及dG-dC交联的水平(R = -0.94,P = 0.005)之间存在显著相关性。在用CNU处理之前,用不同浓度的MNU对SF-188细胞进行预处理,结果N7-HOEtG、N7-ClEtG、O(6)-HOEtdG和PTE的水平没有变化,而N7-双-G、N1-HOEtdG和dG-dC交联的水平呈剂量依赖性增加。综上所述,这些结果表明,N7-双-G、N1-HOEtdG和dG-dC交联的水平可作为用BCNU或相关CENU治疗后治疗反应的分子剂量计。